Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141919 · ClinicalTrials.gov registry record · Phase 2
Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer
A Phase 2 study of Renal Cancers, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02141919 is a Phase 2 study of Renal Cancers that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02141919, a Phase 2 study of Renal Cancers, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
Conditions Studied
Interventions
- RADIATION Stereotactic Ablative Radiation Therapy
Study Locations (1)
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-06 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141919
The ClinicalTrials.gov registry entry for NCT02141919 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cancers appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Ablative Radiation Therapy is the first listed.
NCT02141919 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02141919 about?
NCT02141919 is a clinical study titled "Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer". The goal of this phase II clinical trial is to evaluate the efficacy of the completely non-invasive treatment option of stereotactic radiation therapy for the treatment of biopsy proven and growing small renal tumors.
What is the current status of trial NCT02141919?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-06. Estimated completion is 2026-06.
What conditions does trial NCT02141919 study?
This clinical trial studies the following conditions: Renal Cancers.
What interventions are being tested in trial NCT02141919?
The interventions under investigation include: Stereotactic Ablative Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT02141919?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141919 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.